Assessment of Dose-Dependent Response to Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial

被引：0

作者：

Platzbecker, Uwe ^{[1
]}

Fenaux, Pierre ^{[2
]}

Mufti, Ghulam J. ^{[3
]}

Garcia-Manero, Guillermo ^{[4
]}

Komrokji, Rami S. ^{[5
]}

Buckstein, Rena ^{[6
]}

Diez-Campelo, Maria ^{[7
]}

Finelli, Carlo ^{[8
]}

Sekeres, Mikkael A. ^{[9
]}

Selleslag, Dominik ^{[10
]}

DeZern, Amy E. ^{[11
]}

Quesnel, Bruno ^{[12
]}

Beyne-Rauzy, Odile ^{[13
]}

Voso, Maria Teresa ^{[14
]}

Greenberg, Peter L. ^{[15
]}

Zeidan, Amer M. ^{[16
,17
]}

Ades, Lionel ^{[2
]}

Verma, Amit ^{[18
]}

Savona, Michael R. ^{[19
]}

Laadem, Abderrahmane ^{[20
]}

Ito, Rodrigo ^{[20
]}

Zhang, Jennie ^{[20
]}

Rampersad, Anita ^{[20
]}

Morison, Jessica ^{[20
]}

Louis, Chrystal ^{[20
]}

Linde, Peter G. ^{[21
]}

Santini, Valeria ^{[22
]}

机构：

[1] Univ Hosp Leipzig, Med Clin & Policlin 1, Hematol & Cellular Therapy, Leipzig, Germany

[2] Univ Paris 07, Serv Hematol Seniors, Hop St Louis, Paris, France

[3] Kings Coll London, Dept Haematooncol, London, England

[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[6] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada

[7] Univ Hosp Salamanca, Inst Biomed Res Salamanca, Hematol Dept, Salamanca, Spain

[8] S Orsola Malpighi Univ Hosp, Dept Oncol & Hematol, Bologna, Italy

[9] Cleveland Clin, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA

[10] Acad Hosp St Jan, Dept Haematol, Brugge, Belgium

[11] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[12] Ctr Hosp Univ Lille, Serv Malad Sang, Hop Huriez, Lille, France

[13] Inst Univ Canc Toulouse Oncopole, Med Interne, Toulouse, France

[14] Univ Roma Tor Vergata, Dipartimento Biopatol & Diagnost Immagini, Rome, Italy

[15] Stanford Univ, Canc Ctr, Stanford, CA 94305 USA

[16] Yale Univ, Dept Internal Med, Yale Sch Med, New Haven, CT USA

[17] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[18] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Oncol, New York, NY USA

[19] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA

[20] Bristol Myers Squibb, Princeton, NJ USA

[21] Acceleron Pharma, Cambridge, MA USA

[22] Univ Florence, Azienda Osped Univ AOU Careggi, MDS Unit, Florence, Italy

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷

关键词：

MDS; clinical trial; phase III; myelodysplastic syndromes;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MDS-175

引用

页码：S318 / S318

页数：1

共 50 条

[31] Evaluating the Impact of an Electronic Medical Record (EMR) Alert on Appropriate Dosing of Luspatercept in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Community Oncology Network
Singh, Nisha
Peters, Brooke
Chang, Melody
Maksour, Manale
McMullen, Nicole
Winegar, Bradley
Perkey, Cassandra
Gavrilov, Svetlana
Swanson, Ashley
Slaff, Samantha
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S389 - S390
[32] Benefit of Continuing Luspatercept Therapy in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Who Did Not Achieve Red Blood Cell Transfusion Independence (RBC-TI) by Week 25 in the MEDALIST Study
Platzbecker, Uwe
Germing, Ulrich
Fenaux, Pierre
Buckstein, Rena
Santini, Valeria
Diez-Campelo, Maria
Tang, Derek
Ito, Rodrigo
Fabre, Shannon
Mantovani, Emily
Zhang, George
Ha, Xianwei
Miteva, Dimana
Hughes, Christina
Khan, Wasiulla
Komrokji, Rami S.
Garcia-Manero, Guillermo
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 142 - 143
[33] A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry
Buckstein, Rena
Chodirker, Lisa
Mozessohn, Lee
Yee, Karen W. L.
Geddes, Michelle
Zhu, Nancy
Shamy, April
Leitch, Heather A.
Christou, Grace
Banerji, Versha
Brian, Leber
Khalaf, Dina
St-Hilaire, Eve
Finn, Nicholas
Nevill, Thomas
Keating, Mary-Margaret
Storring, John
Delage, Robert
Parmentier, Anne
Thambipillai, Aksharh
Siddiqui, Mohammed
Westcott, Christopher
Cameron, Chris
Mamedov, Alexandre
Spin, Paul
Tang, Derek
LEUKEMIA & LYMPHOMA, 2022, 63 (13) : 3165 - 3174
[34] PHASE 1 STUDY EVALUATING LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS
Garcia-Manero, G.
Bachiashvili, K.
Amin, H.
Traer, E.
Pollyea, D.
Sallman, D.
Al-Kali, A.
Cripe, L.
Berdeja, J.
Griffiths, E.
Mohan, S.
Vachhani, P.
Sano, Y.
Oganesian, A.
Keer, H.
Yacoub, A.
LEUKEMIA RESEARCH, 2023, 128
[35] Characterization of Patients with Lower-Risk Myelodysplastic Syndromes Experiencing Long-Term Responses with Luspatercept in the MEDALIST Study
Platzbecker, Uwe
Santini, Valeria
Komrokji, Rami S.
Zeidan, Amer M.
Garcia-Manero, Guillermo
Buckstein, Rena
Oliva, Esther Natalie
Miteva, Dimana
Pozharskaya, Veronika
Ha, Xianwei
Nadal, Jose Alberto
Fenaux, Pierre
BLOOD, 2022, 140 : 9808 - 9810
[36] Mutational Profile and Analysis of Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Luspatercept: Phase 2 PACE-MDS Study
Platzbecker, Uwe
Kiewe, Philipp
Germing, Ulrich
Gotze, Katharina S.
Mayer, Karin
Radsak, Markus P.
Wolff, Thomas
Chromik, Joerg
Wilson, Dawn
Zhang, Xiaosha
Rovaldi, Chris
Laadem, Abderrahmane
Sherman, Matthew Leigh
Attie, Kenneth Morris
Reynolds, Joseph
Linde, Peter Guest
Giagounidis, Aristoteles
BLOOD, 2017, 130
[37] Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study
Platzbecker, Uwe
Santini, Valeria
Komrokji, Rami S.
Zeidan, Amer M.
Garcia-Manero, Guillermo
Buckstein, Rena
Oliva, Esther Natalie
Pozharskaya, Veronika
Ha, Xianwei
Nadal, Jose Alberto
Miteva, Dimana
Fenaux, Pierre
BLOOD, 2022, 140 : 6971 - 6973
[38] Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive transfusion-dependent (TD) patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS).
Garcia-Manero, Guillermo
Platzbecker, Uwe
Santini, Valeria
Zeidan, Amer Methqal
Fenaux, Pierre
Komrokji, Rami S.
Shortt, Jake
Valcarcel, David
Jonasova, Anna
Dimicoli-Salazar, Sophie
Tiong, Ing Soo
Lin, Chien-Chin
Li, Jiahui
Kreitz, Sandra
Pozharskaya, Veronika
Shetty, Jeevan K.
Degulys, Andrius
Finelli, Carlo
Cluzeau, Thomas
Della Porta, Matteo Giovanni
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[39] Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial
Garcia-Manero, Guillermo
Platzbecker, Uwe
Santini, Valeria
Zeidan, Amer M.
Fenaux, Pierre
Komrokji, Rami S.
Shortt, Jake
Valcarcel, David
Jonasova, Anna
Dimicoli-Salazar, Sophie
Tiong, Ing Soo
Lin, Chien-Chin
Li, Jiahui
Zhang, Jennie
Giuseppi, Ana Carolina
Kreitz, Sandra
Pozharskaya, Veronika
Keeperman, Karen L.
Rose, Shelonitda
Prebet, Thomas
Degulys, Andrius
Paolini, Stefania
Cluzeau, Thomas
Della Porta, Matteo Giovanni
BLOOD, 2023, 142
[40] Clinical Benefit of Luspatercept in Patients With Lower-Risk MDS and High Transfusion Burden in the Phase III MEDALIST Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 7 - 9

← 1 2 3 4 5 →